| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland
The regulatory peptide gastrin-releasing peptide (GRP) may play a role in human cancer as a stimulatory growth factor. To understand the potential role of GRP in human breast cancer, we have evaluated GRP receptor expression in human non-neoplastic and neoplastic breast tissues and in axillary lymph node metastases, using in vitro receptor autoradiography on tissue sections with [125I]Tyr4-bombesin and with [125I]D-Tyr6, ß Ala11, Phe13, Nle14-bombesin(6–14) as radioligands. GRP receptors were detected, often in high density, in neoplastic epithelial mammary cells in 29 of 46 invasive ductal carcinomas, in 11 of 17 ductal carcinomas in situ, in 1 of 4 invasive lobular carcinomas, in 1 of 2 lobular carcinomas in situ, and in 1 mucinous and 1 tubular carcinoma. A heterogeneous GRP receptor distribution was found in the neoplastic tissue samples in 32 of 52 cases with invasive carcinoma and 12 of 19 cases with carcinoma in situ. The lymph node metastases (n = 33) from those primary carcinomas expressing GRP receptors were all positive, whereas surrounding lymphoreticular tissue was negative. GRP receptors were also present in high density but with heterogeneous distribution in ducts and lobules from all available breast tissue samples (n = 23). All of the receptors corresponded to the GRP receptor subtype of bombesin receptors, having high affinity for GRP and bombesin and lower affinity for neuromedin B. All tissues expressing GRP receptors were identified similarly with both radioligands. These data describe not only a high percentage of GRP receptor-positive neoplastic breast tissues but also for the first time a ubiquitous GRP receptor expression in nonneoplastic human breast tissue. Apart from suggesting a role of GRP in breast physiology, these data represent the molecular basis for potential clinical applications of GRP analogs such as GRP receptor scintigraphy, radiotherapy, or chemotherapy.
This article has been cited by other articles:
 |
|
 |
|
  R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Van de Wiele, P. Phonteyne, P. Pauwels, I. Goethals, R. Van den Broecke, V. Cocquyt, and R. A. Dierckx Gastrin-Releasing Peptide Receptor Imaging in Human Breast Carcinoma Versus Immunohistochemistry J. Nucl. Med., February 1, 2008; 49(2): 260 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Cescato, T. Maina, B. Nock, A. Nikolopoulou, D. Charalambidis, V. Piccand, and J. C. Reubi Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting J. Nucl. Med., February 1, 2008; 49(2): 318 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cornelio, R Roesler, and G Schwartsmann Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Ann. Onc., September 1, 2007; 18(9): 1457 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B Engel, A. V Schally, G. Halmos, B. Baker, A. Nagy, and G. Keller Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins Endocr. Relat. Cancer, December 1, 2005; 12(4): 999 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maina, B. A. Nock, H. Zhang, A. Nikolopoulou, B. Waser, J.-C. Reubi, and H. R. Maecke Species Differences of Bombesin Analog Interactions with GRP-R Define the Choice of Animal Models in the Development of GRP-R-Targeting Drugs J. Nucl. Med., May 1, 2005; 46(5): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schuhmacher, H. Zhang, J. Doll, H. R. Macke, R. Matys, H. Hauser, M. Henze, U. Haberkorn, and M. Eisenhut GRP Receptor-Targeted PET of a Rat Pancreas Carcinoma Xenograft in Nude Mice with a 68Ga-Labeled Bombesin(6-14) Analog J. Nucl. Med., April 1, 2005; 46(4): 691 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Matusiak, S. Glover, R. Nathaniel, K. Matkowskyj, J. Yang, and R. V. Benya Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon Am J Physiol Gastrointest Liver Physiol, April 1, 2005; 288(4): G718 - G728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Reubi, H. R. Macke, and E. P. Krenning Candidates for Peptide Receptor Radiotherapy Today and in the Future J. Nucl. Med., January 1, 2005; 46(1_suppl): 67S - 75S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Maecke, M. Hofmann, and U. Haberkorn 68Ga-Labeled Peptides in Tumor Imaging J. Nucl. Med., January 1, 2005; 46(1_suppl): 172S - 178S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, J. Chen, C. Waldherr, K. Hinni, B. Waser, J. C. Reubi, and H. R. Maecke Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors Cancer Res., September 15, 2004; 64(18): 6707 - 6715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-J. Gao, J.-H. Deng, and F.-C. Zhou Productive Lytic Replication of a Recombinant Kaposi's Sarcoma-Associated Herpesvirus in Efficient Primary Infection of Primary Human Endothelial Cells J. Virol., September 15, 2003; 77(18): 9738 - 9749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reubi, B. Waser, W. Vale, and J. Rivier Expression of CRF1 and CRF2 Receptors in Human Cancers J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3312 - 3320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A.P. Breeman, M. de Jong, J. L. Erion, J. E. Bugaj, A. Srinivasan, B. F. Bernard, D. J. Kwekkeboom, T. J. Visser, and E. P. Krenning Preclinical Comparison of 111In-Labeled DTPA- or DOTA-Bombesin Analogs for Receptor-Targeted Scintigraphy and Radionuclide Therapy J. Nucl. Med., December 1, 2002; 43(12): 1650 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Saurin, M. Fallavier, B. Sordat, J.-C. Gevrey, J.-A. Chayvialle, and J. Abello Bombesin Stimulates Invasion and Migration of Isreco1 Colon Carcinoma Cells in a Rho-dependent Manner Cancer Res., August 15, 2002; 62(16): 4829 - 4835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reubi, S. Wenger, J. Schmuckli-Maurer, J.-C. Schaer, and M. Gugger Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand 125I-[D-TYR6, {beta}-ALA11, PHE13, NLE14] Bombesin(6-14) Clin. Cancer Res., April 1, 2002; 8(4): 1139 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Bajo, A. V. Schally, M. Krupa, F. Hebert, K. Groot, and K. Szepeshazi Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes PNAS, March 19, 2002; 99(6): 3836 - 3841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Lango, K. F. Dyer, V. W. Y. Lui, W. E. Gooding, C. Gubish, J. M. Siegfried, and J. R. Grandis Gastrin-Releasing Peptide Receptor-Mediated Autocrine Growth in Squamous Cell Carcinoma of the Head and Neck J Natl Cancer Inst, March 6, 2002; 94(5): 375 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Van de Wiele, F. Dumont, R. A. Dierckx, S. H. Peers, J. R. Thornback, G. Slegers, and H. Thierens Biodistribution and Dosimetry of 99mTc-RP527, a Gastrin-Releasing Peptide (GRP) Agonist for the Visualization of GRP Receptor-Expressing Malignancies J. Nucl. Med., November 1, 2001; 42(11): 1722 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Reubi, M. Gugger, B. Waser, and J.-C. Schaer Y1-Mediated Effect of Neuropeptide Y in Cancer: Breast Carcinomas as Targets Cancer Res., June 1, 2001; 61(11): 4636 - 4641. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
